VantAI announced today that it has entered into a second expansion of its collaboration and license agreement with Blueprint Medicines.

VantAI launches Neo-1, the first AI model to rewire molecular interactions by unifying structure prediction and generation for therapeutic design.

VantAI, a company focused on generative AI-enabled drug discovery, today announced the appointments of Dr. Ian Churcher and Dr. Bradley Pentelute to its Scientific Advisory Board (SAB).

VantAI, a leader in generative AI and drug discovery, today announced the appointment of John Cuozzo, PhD as SVP, Head of Drug Discovery. Cuozzo is an experienced scientific leader with a strong track record of building novel discovery platforms and leading successful drug discovery programs.

VantAI will leverage its proprietary large scale structural data and NVIDIA H100 GPUs on Google Cloud to enable a step-change in accuracy for all-atom protein interaction prediction.

VantAI, a company focused on generative AI-enabled drug discovery, and Bristol Myers Squibb, a leading pharmaceutical company, have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest.

VantAI, a leader in generative AI and drug discovery, announced the appointment of Jae Won Kim as Chief Operating Officer (COO) and Chief Financial Officer (CFO). Ms. Kim is an experienced finance, corporate development, and operations executive with a strong track record, especially in drug discovery and the induced proximity landscape.

VantAI, a leader in the fields of drug discovery and generative AI, announced today it has entered into an amended and restated collaboration and license agreement with Blueprint Medicines, a leading precision medicine company, to design and advance novel targeted protein degrader therapies to address important areas of medical need.

VantAI, a leading company focused on the application of artificial intelligence to drug discovery, today announced its newly formed Scientific Advisory Board (SAB). VantAI’s SAB members are experts in protein design, whole-proteome structural interactomics, and generative AI for small molecule drug design

Dr. Bronstein, the DeepMind Professor of AI at Oxford, will help VantAI unlock the potential of induced proximity

VantAI will pair its induced proximity platform with BI’s deep early discovery experience to identify targeted protein degraders with enhanced properties for traditionally “undruggable” targets

VantAI, an AI-first induced-proximity company, today announced it has entered into a multi-year collaboration agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson

Collaboration will leverage Proteovant's Artificial Intelligence-enhanced targeted protein degradation platform and Blueprint Medicines' small molecule precision medicine capabilities to address medical needs in oncology and hematology